Halia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial
Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initial positive data in patients with an early form of blood cancer that affects the bone marrow. The...
View ArticleCardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offering
Cardiff Oncology announced an oversubscribed $40 million offering on Tuesday after it released positive data from a mid-stage trial investigating its onvansertib combo in patients with first-line...
View Article#ASH24: J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of...
Johnson & Johnson and Legend Biotech say their CAR-T therapy Carvykti has the potential to remove all traces of disease from certain blood cancer patients based on the latest results of a Phase 3...
View ArticleCases of severe RSV in two Moderna vaccine candidates' trials raise questions...
Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children and infants are currently on hold, including two not previously disclosed by...
View ArticleWalgreens in talks to sell to private equity — report
Walgreens is reportedly in discussions to sell itself to a private equity firm as the retail pharmacy giant grapples with store closures and slumping shares. The deal with New York-based private equity...
View ArticleExclusive: Two Vida Ventures co-founders exit the VC firm
Arjun Goyal and Stefan Vitorovic, two of Vida Ventures' three co-founding managing directors, have exited the firm as it rejigs its leadership team seven years after launching. They were both...
View ArticleUniQure stock doubles after FDA meeting on Huntington's disease
Dutch-based uniQure saw its stock {$QURE} rise by more than 120% on Tuesday after it disclosed that it is "in alignment" with the FDA on using the accelerated approval pathway for its experimental...
View ArticleNewAmsterdam hits primary endpoint in CETP inhibitor trial
NewAmsterdam Pharma’s cardio drug succeeded in a third readout this year, showing that obicetrapib could lower a type of lipoprotein that carries cholesterol in the blood. The BROADWAY trial hit on ...
View Article#ASH24: Early data on BTK degraders suggest promise of next-gen approach
SAN DIEGO — Drug developers are making a new generation of treatments for blood cancers that arise from abnormal B cells by taking advantage of the body’s natural protein recycling system. BeiGene
View ArticleContending with Americans’ fury at health insurers
Since last week's shooting and death of UnitedHealthcare CEO Brian Thompson, there's been a wave of frustration expressed with the health insurance industry, and support for the alleged killer. The...
View ArticleBayer exits Europe pact with Moberg for nail fungus drug after Phase 3 fail
Moberg Pharma’s Terclara has flunked a late-stage test evaluating less frequent maintenance dosing for fungal nail infection, prompting Bayer to pull out of planned launch activities in Europe and...
View ArticleNegev Labs debuts with $30M in assets, striving to build a network of...
A new psychedelic-focused startup incubator is debuting, backed by an investor behind some of the most prominent biotechs in the space. The main theme of the companies it wants to build? No tripping....
View ArticleExclusive: Angitia, a Bain-backed musculoskeletal biotech, raises $120M for...
Angitia Biopharmaceuticals, a California and China biotech developing musculoskeletal biologics, has closed a $120 million Series C led by Bain Capital Life Sciences, the drug developer exclusively...
View ArticleGenetic medicine startups Chroma, Nvelop merge into nChroma
What started as two CEOs eating tacos and talking biotech led to a merger and a new company. The epigenetic editing startup Chroma Medicine and the delivery specialist Nvelop Therapeutics said...
View ArticleThe Endpoints 100 Survey: Biotech industry braces for Trump 2.0
Big changes are afoot at the FDA in the wake of Donald Trump’s reelection, and there’s considerable anxiety in senior biotech ranks that an upheaval in the agency could trigger both an exodus of...
View Article#SABCS24: Lilly’s oral SERD makes strides in breast cancer with Phase 3 data
Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or death among patients with mutated estrogen receptor genes, but not in all...
View ArticleAcelyrin says goodbye to the drug that got it a $540M IPO in 2023
Acelyrin is officially ending development of an experimental medicine it referred to as a "diamond in the rough" and that served as the foundation for one of the
View Article#ASH24: Gene editing companies seek safer, less grueling conditioning methods...
SAN DIEGO — New and experimental gene therapies made with blood stem cells rely on the same grueling, decades-old methods for a process called conditioning that’s used for bone marrow transplants. It’s...
View Article